Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2016

Open Access 01-12-2016 | Research article

Acute glycaemic effects of co-trimoxazole at prophylactic dose in healthy adults

Authors: Bernold Kenteu, Jean Jacques N. Noubiap, Martine Claude Etoa, Marcel Azabji-Kenfack, Mesmin Dehayem, Eugene Sobngwi

Published in: BMC Endocrine Disorders | Issue 1/2016

Login to get access

Abstract

Background

Cases of severe hypoglycaemia were reported in HIV/AIDS patients receiving high dose of the sulfonylurea co-trimoxazole for opportunistic infections. Whether co-trimoxazole at prophylactic dose would induce similar side effects is unknown. We aimed to investigate the acute effects of co-trimoxazole at prophylactic dose on glucose metabolism in healthy adults.

Methods

We enrolled 20 healthy volunteers (15 males and 5 females) aged 23.0 (SD 2.0) years, with mean BMI of 22.3 (SD 3.6) Kg/m2 with normal glucose tolerance, hepatic and renal function. We performed a 75-g oral glucose tolerance test (OGTT) with and without concomitant oral co-trimoxazole administered 60 min before the test. Blood glucose response was measured using a capillary test at baseline and at 30, 60, 90, 120 and 180 min following oral glucose load on the two occasions. C-peptide response was also measured. Absolute values of blood glucose and C-peptide with and without co-trimoxazole were compared using the Wilcoxon test.

Results

During the OGTT without co-trimoxazole (control) vs. the OGTT with co-trimoxazole (test), the glycaemia varied from 4.83 (SD 0.39) mmol/l vs. 4.72 (SD 0.28) mmol/l at T0 (P = 0.667), to 8.00 (SD 1.11) mmol/l vs. 7.44 (SD 0.78) mmol/l at T30 (P = 0.048), 8.00 (SD 1.17) mmol/l vs. 7.67 (SD 1.00) mmol/l at T60 (P = 0.121), 7.33 (SD 0.94) mmol/l vs. 7.11 (SD 0.83) mmol/l at T90 (P = 0.205), 6.78 (SD 1.00) mmol/l vs. 6.67 (SD 1.00) mmol/l at T120 (P = 0.351) and 4.72 (SD 1.39) mmol/l vs. 4.72 (SD 1.56) mmol/l at T180 (P = 0.747). The ratio of area under the glycaemia curve during the control and test investigation was 96.7 %, thus a 3.3 decreased glycaemic response (p = 0.062). A decrease of glycaemia by more than 10 % occurred in 6/20 participants at T30, 7/20 participants at T60 and 1/20 participant at T30 and T60. None of the volunteers experienced co-trimoxazole-induced hypoglycaemia. At the same time, the C-peptide response during the control vs. the test investigation varied from 278.1 (SD 57.5) pmol/l vs. 242.8 (SD 42.5) pmol/l at T0 (P = 0.138), to 1845.6 (SD 423.6) pmol/l vs. 2340.6 (SD 701.3) pmol/l at T60 (P = 0.345) and 1049.8 (SD 503.1) pmol/l vs. 1041.63 (SD 824.21) pmol/l at T180 (P = 0.893).

Conclusion

Ninety minutes after its administration, co-trimoxazole induced a significant reduction of the early glycaemic response to oral glucose in parallel with a 27-% increase in insulin secretory response. Co-trimoxazole induced within 120 min a more than 10-% blood glucose reduction in 2/3 of participants. However none of the volunteers experienced hypoglycaemia.
Literature
1.
go back to reference Cheng W, Wu Y, Wen Y, Ma Y, Zhao D, Dou Z, et al. Cotrimoxazole prophylaxis and antiretroviral therapy: an observational cohort study in China. Bull World Health Organ. 2015;93(3):152–60.CrossRefPubMedPubMedCentral Cheng W, Wu Y, Wen Y, Ma Y, Zhao D, Dou Z, et al. Cotrimoxazole prophylaxis and antiretroviral therapy: an observational cohort study in China. Bull World Health Organ. 2015;93(3):152–60.CrossRefPubMedPubMedCentral
2.
go back to reference Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet Lond Engl. 2004;364(9443):1428–34.CrossRef Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet Lond Engl. 2004;364(9443):1428–34.CrossRef
4.
go back to reference Strevel EL, Kuper A, Gold WL. Severe and protracted hypoglycaemia associated with co-trimoxazole use. Lancet Infect Dis. 2006;6(3):178–82.CrossRefPubMed Strevel EL, Kuper A, Gold WL. Severe and protracted hypoglycaemia associated with co-trimoxazole use. Lancet Infect Dis. 2006;6(3):178–82.CrossRefPubMed
5.
go back to reference Nunnari G, Celesia BM, Bellissimo F, Tosto S, La Rocca M, Giarratana F, et al. Trimethoprim-sulfamethoxazole-associated severe hypoglycaemia: a sulfonylurea-like effect. Eur Rev Med Pharmacol Sci. 2010;14(12):1015–8.PubMed Nunnari G, Celesia BM, Bellissimo F, Tosto S, La Rocca M, Giarratana F, et al. Trimethoprim-sulfamethoxazole-associated severe hypoglycaemia: a sulfonylurea-like effect. Eur Rev Med Pharmacol Sci. 2010;14(12):1015–8.PubMed
6.
go back to reference Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S. Anti-infectives and risk of severe hypoglycemia in glipizide and glyburide users. Clin Pharmacol Ther. 2010;88(2):214–22.CrossRefPubMedPubMedCentral Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S. Anti-infectives and risk of severe hypoglycemia in glipizide and glyburide users. Clin Pharmacol Ther. 2010;88(2):214–22.CrossRefPubMedPubMedCentral
7.
go back to reference Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest. 1987;79(3):777–81.CrossRefPubMedPubMedCentral Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest. 1987;79(3):777–81.CrossRefPubMedPubMedCentral
8.
go back to reference Hekimsoy Z, Biberoǧlu S, Çömlekçi A, Tarhan O, Mermut C, Biberoǧlu K. Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection. Eur J Endocrinol. 1997;136(3):304–6.CrossRefPubMed Hekimsoy Z, Biberoǧlu S, Çömlekçi A, Tarhan O, Mermut C, Biberoǧlu K. Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection. Eur J Endocrinol. 1997;136(3):304–6.CrossRefPubMed
9.
go back to reference Arem R, Garber AJ, Field JB. Sulfonamide-induced hypoglycemia in chronic renal failure. Arch Intern Med. 1983;143(4):827–9.CrossRefPubMed Arem R, Garber AJ, Field JB. Sulfonamide-induced hypoglycemia in chronic renal failure. Arch Intern Med. 1983;143(4):827–9.CrossRefPubMed
Metadata
Title
Acute glycaemic effects of co-trimoxazole at prophylactic dose in healthy adults
Authors
Bernold Kenteu
Jean Jacques N. Noubiap
Martine Claude Etoa
Marcel Azabji-Kenfack
Mesmin Dehayem
Eugene Sobngwi
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2016
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-016-0142-6

Other articles of this Issue 1/2016

BMC Endocrine Disorders 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.